Source: Annual Congress 2005 - Health status in COPD and asthma: its relevance in pulmonary rehabilitation
Disease area: Airway diseases

Abstract

Aim of the study: to evaluate the changes of pulmonary artery average pressure (Pap), clinical symptoms and lung function (LF) in moderate and severe COPD patients with PH treated by bronchodilators.
Materials and methods:12 moderate and 18 severe COPD patients (previously not treated by bronchodilators) with Pap≥20 mm Hg underwent 24 weeks prospective controlled parallel group study with single treatment regimen in both groups (fenoterol+ipratropium, 50 mcg+20mcg, MDI,2 puffs q.i.d.).Clinical symptoms, evaluated using symptom score(SS), LF testing (FVC, VC, FEV ₁, PEFR; Master Lab,Erich Jaeger), were performed at baseline, after 4,12, 24 weeks. Average Pap measurements (Doppler echocardiography, Konton Sigma 44) were conducted at baseline, after 12, 24 weeks.
Results demonstrated a significant decrease (p<0.05) in comparison with baseline characteristics of SS from 7.4±0.7 to 0.9±0.2 in moderate and from 7.7±0.5 to 2.2±0.3 in severe patients, Pap from 33.9±1.4 to 20.8±1.7 and from 31.2±1.1 to 24.9±1.5 and increase of FEV ₁ from 62.2±1.7 to 76.4±1.9 and from 38.0±2.3 to 59.3±3.1 in moderate and severe patients correspondingly. The improvement of symptoms and LFT was more expressed in moderate COPD patients (p<0.05), but the decreasing of Pap was similar in both groups.
Conclusion: maintained bronchodilator therapy in moderate and severe COPD patients with pulmonary hypertension decreases symptoms, improves lung function and leads to decrease of Pap.

Rating:

Share or cite this content

Citations should be made in the following way:
M. Khmelkova, Z. Grineva, E. Shmelev (Moscow, Russian Federation). Influence of bronchodilators on pulmonary hypertension (PH) in patients with moderate and severe chronic obstructive pulmonary disease (COPD). Eur Respir J 2005; 26: Suppl. 49, 2053

Member's Comments

No comment yet.

Related content which might interest you: Influence of bronchodilators on pulmonary hypertension in patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2003; 22: Suppl. 45, 427s Year: 2003 Influence of bronchodilators on pulmonary hypertension in patients with chronic obstructive pulmonary disease (COPD) and COPD concomitant with bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 521s Year: 2004 Effects of amlodipine on pulmonary haemodynamics in pulmonary hypertension (PH) secondary to chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 27s Year: 2002 The state of patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2007; 30: Suppl. 51, 547s Year: 2007 Enalapril in the management of patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2003; 22: Suppl. 45, 241s Year: 2003 Acute effects of sildenafil in chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008 Conclusion: treatment of pulmonary hypertension in COPD patients Source: Annual Congress 2005 - COPD - pulmonary haemodynamics and gas exchange Year: 2005 Effects of Valsartan on pulmonary hemodynamics in patients with chronic obstructive pulmonary disease (COPD) and secondary pulmonary hypertension Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies Year: 2019 Benefits of pulmonary rehabilitation (PR) in patients with chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) having the same dyspnoea severity Source: International Congress 2018 – What’s hot in rehabilitation in COPD and interstitial lung disease (ILD)? Year: 2018 The effect of dipyrone on respiratory function in chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2004; 24: Suppl. 48, 290s Year: 2004 Antibiotics in the exacerbations of severe and very severe chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Microbiology and treatment of bronchiectasis and exacerbations of COPD Year: 2008 Systemic and pulmonary inflammation in chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Pathophysiology of COPD Year: 2008 Subclinical cardiac dysfunction in moderate to severe chronic obstructive pulmonary disease (COPD) patients Source: Annual Congress 2011 - COPD management Year: 2011 Predictors of arrhythmias in patients with chronic obstructive pulmonary disease (COPD). Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies Year: 2019 Bronchiectasis impact outcomes in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Microbiology and treatment of bronchiectasis and exacerbations of COPD Year: 2008 The safety of sputum induction in patients with exacerbation of severe and very severe COPD (chronic obstructive pulmonary disease) Source: Annual Congress 2008 - Organisation of care and management of COPD Year: 2008 Platelet characteristics of patients with chronic obstructive pulmonary disease (COPD) accompanied with lung hypertension Source: Eur Respir J 2007; 30: Suppl. 51, 226s Year: 2007 Effect of hospitalization on exercise capacity in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2012 - Methodology in epidemiologic research Year: 2012 Reversibility of airflow limitation in patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2004; 24: Suppl. 48, 587s Year: 2004 Large airways remodeling in chronic obstructive pulmonary disease (COPD) patients Source: Annual Congress 2008 - Pathophysiology of respiratory diseases Year: 2008